You are here

Survey: Gastroenterologists Applaud Cell Adhesion Molecule Inhibitor Vedolizumab (Entyvio)

Treatment offers different mechanism of action

Decision Resources Group, a health care research firm located in Burlington, Mass., has found that at 1 month post-launch, most surveyed gastroenterologists were aware of and familiar with vedolizumab (Entyvio, Takeda) as a new therapy for the treatment of moderate-to-severe ulcerative colitis (UC) and/or Crohn’s disease (CD).

According to surveyed gastroenterologists, the most commonly cited advantage of vedolizumab compared with other currently available biologic treatments was its different mechanism of action. At 1 month post-launch, less than 20% of surveyed gastroenterologists reported prescribing vedolizumab to their UC and/or CD patients.

Less than half of surveyed gastroenterologists were satisfied with the currently available products for moderate-to-severe UC and/or CD, and most agreed that there is a need for alternative therapies.

Although the risk of progressive multifocal leukoencephalopathy associated with vedolizumab was a concern for most surveyed gastroenterologists, most of the respondents anticipated prescribing the agent to their patients with UC and/or CD within 1 year.

According to surveyed gastroenterologists, tumor necrosis factor (TNF)-refractory patients with UC and/or CD are the ideal candidates for treatment with vedolizumab. Infliximab (Remicade, Janssen Biotech) and adalimumab (Humira, AbbVie) are likely to remain the first-line biologic agents for patients with moderate-to-severe UC and/or CD.

“High opportunity exists for emerging therapies in the inflammatory bowel disease market,” said analyst Adi Reske, PhD. “Improved efficacy in the acute and maintenance setting, long-term safety, and more convenient dosing formulations are the highly desired attributes for products in development for UC and CD.”

Source: BioTrends Research Group; September 29, 2014.

Recent Headlines

Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs